Not recruiting
Primary immunodeficiency syndrome
Not recruitingStudy on Long-term Safety of TAK-881 (Human Normal Immunoglobulin, Hyaluronidase) for Patients with Primary Immunodeficiency Diseases
InvestigationalNo placebo
Study on Long-term Safety of TAK-881 (Human Normal Immunoglobulin, Hyaluronidase) for Patients with Primary Immunodeficiency Diseases
InvestigationalNo placebo
- Disease:Primary immunodeficiency syndrome
- Substances:Human Normal ImmunoglobulinHyaluronidase (Human Recombinant)
Countries:
Germany
Germany- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Human Normal Immunoglobulin